Day One Biopharmaceuticals (NASDAQ:DAWN) Issues Earnings Results

Day One Biopharmaceuticals (NASDAQ:DAWN) announced its earnings results on Tuesday. The company reported ($0.69) EPS for the quarter, missing analysts’ consensus estimates of ($0.35) by ($0.34), Zacks reports.

Day One Biopharmaceuticals Stock Performance

NASDAQ:DAWN traded down $0.36 during trading hours on Tuesday, hitting $11.82. The company’s stock had a trading volume of 1,385,338 shares, compared to its average volume of 985,204. The company has a market capitalization of $1.19 billion, a PE ratio of -11.48 and a beta of -1.46. Day One Biopharmaceuticals has a 52-week low of $11.13 and a 52-week high of $18.07. The business’s 50-day moving average is $12.36 and its two-hundred day moving average is $13.47.

Insider Transactions at Day One Biopharmaceuticals

In other Day One Biopharmaceuticals news, CFO Charles N. York II sold 4,370 shares of the company’s stock in a transaction dated Tuesday, February 18th. The shares were sold at an average price of $11.96, for a total transaction of $52,265.20. Following the transaction, the chief financial officer now directly owns 252,638 shares in the company, valued at approximately $3,021,550.48. This represents a 1.70 % decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which can be accessed through this link. Also, insider Samuel C. Blackman sold 30,000 shares of the stock in a transaction dated Tuesday, December 10th. The shares were sold at an average price of $13.31, for a total transaction of $399,300.00. Following the completion of the transaction, the insider now directly owns 1,034,015 shares of the company’s stock, valued at approximately $13,762,739.65. This trade represents a 2.82 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold a total of 51,064 shares of company stock valued at $651,225 in the last ninety days. 8.40% of the stock is currently owned by company insiders.

Analyst Upgrades and Downgrades

DAWN has been the topic of several research reports. Needham & Company LLC reissued a “buy” rating and set a $33.00 price objective on shares of Day One Biopharmaceuticals in a research report on Monday, January 13th. The Goldman Sachs Group dropped their price target on Day One Biopharmaceuticals from $48.00 to $43.00 and set a “buy” rating on the stock in a research report on Monday, February 10th. Bank of America decreased their price objective on Day One Biopharmaceuticals from $28.00 to $25.00 and set a “buy” rating for the company in a research report on Tuesday, January 7th. HC Wainwright reissued a “buy” rating and issued a $40.00 target price on shares of Day One Biopharmaceuticals in a report on Thursday, October 31st. Finally, TD Cowen upgraded Day One Biopharmaceuticals to a “strong-buy” rating in a research note on Monday, November 4th. One analyst has rated the stock with a hold rating, seven have assigned a buy rating and one has assigned a strong buy rating to the company. According to data from MarketBeat.com, Day One Biopharmaceuticals presently has an average rating of “Buy” and an average target price of $35.71.

About Day One Biopharmaceuticals

Day One Biopharmaceuticals, Inc, a clinical-stage biopharmaceutical company, develops and commercializes targeted therapies for patients with genomically defined cancers. Its lead product candidate is tovorafenib, an oral brain-penetrant type II pan-rapidly accelerated fibrosarcoma kinase inhibitor that is in Phase II clinical trial for pediatric patients with relapsed/ refractory low-grade glioma.